Acro Biomedical Co, LTD 10-Q quarterly reports

Acro Biomedical Co., Ltd. reported no revenue for the first quarter of 2026, with net losses widening to $43,774, primarily due to operating expenses and interest on related party loans.

Acro Biomedical Co., Ltd. reported a significant increase in net loss for Q3 2025, with no revenue generated since late 2022, raising substantial doubt about its ability to continue as a going concern.

Acro Biomedical Co., Ltd. reported continued net losses and no revenue for the second quarter and first half of 2025, raising substantial doubt about its ability to continue as a going concern.

Acro Biomedical Co., Ltd. reported no revenue for Q1 2025, continued operating losses, and significant doubt about its ability to continue as a going concern, relying heavily on related party advances.

Acro Biomedical Co., Ltd. reported no revenue for the third quarter and first nine months of 2024, with a growing accumulated deficit and significant going concern doubts.

Acro Biomedical reports no revenue, continued losses, and significant going concern issues for Q2 2024, relying solely on related party advances.

Acro Biomedical Co., Ltd. reported no revenue and a critically low cash balance for Q1 2024, raising substantial doubt about its ability to continue operations.

Acro Biomedical Co., Ltd. reported no revenue for the nine months ended September 30, 2023, a significant net loss, and a negative working capital, raising substantial doubt about its ability to continue as a going concern.